Author Affiliations: Division of Epidemiology–I, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland (Dr Hampp); and Pharmaceutical Outcomes and Policy, College of Pharmacy (Drs Kauf and Winterstein), Department of Pediatrics, College of Medicine (Dr Saidi), and Department of Epidemiology and Biostatistics, College of Public Health and Health Professions (Dr Winterstein), University of Florida, Gainesville.
We thank Mahadevia and colleagues for their interest in our article1 and welcome this opportunity to address their comments and concerns.
Mahadevia et al seem to imply that our study was of questionable quality because we used cost per avoided hospitalization rather than quality-adjusted life-years saved. Their claim was based on a review by Smart et al2 that was conducted prior to the publication of our study. It is disingenuous and incorrect to generalize the overall findings from the review as suggesting that economic evaluations relying on observational data and/or not incorporating utilities are necessarily of low quality.
Hampp C, Kauf TL, Saidi AS, Winterstein AG. Methodological Concerns Regarding Cost-effectiveness Analysis of Palivizumab in Florida Medicaid—Reply. Arch Pediatr Adolesc Med. 2012;166(10):968-970. doi:10.1001/archpediatrics.2012.1594